* Acrivon Therapeutics press release [https://seekingalpha.com/pr/20200234-acrivon-therapeutics-reports-second-quarter-2025-financial-results-and-business-highlights] (NASDAQ:ACRV [https://seekingalpha.com/symbol/ACRV]): Q2 GAAP EPS of -$0.55.
*
Research and development expenses were $16.2 million for the quarter ended June 30, 2025 compared to $15.0 million for the same period in 2024. The difference was primarily due to increased personnel to support the continued execution of the clinical trials for ACR-368 and ACR-2316, as well as preclinical drug discovery advancement.
General and administrative expenses were $6.5 million for the quarter ended June 30, 2025, which is materially consistent with $6.4 million for the same period in 2024.
As of June 30, 2025, the company had cash, cash equivalents and investments of $147.6 million, which is expected to fund operating expenses and capital expenditure requirements into the second quarter of 2027.
*
MORE ON ACRIVON THERAPEUTICS
* Seeking Alpha’s Quant Rating on Acrivon Therapeutics [https://seekingalpha.com/symbol/ACRV/ratings/quant-ratings]
* Historical earnings data for Acrivon Therapeutics [https://seekingalpha.com/symbol/ACRV/earnings]
* Financial information for Acrivon Therapeutics [https://seekingalpha.com/symbol/ACRV/income-statement]
Acrivon Therapeutics GAAP EPS of -$0.55
Published 2 months ago
Aug 13, 2025 at 8:41 PM
Positive
Auto